EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The incidence of and risk factors for radiation pneumonitis in patients treated with simultaneous bevacizumab and thoracic radiotherapy

Feihu Chen, Jiling Niu, Min Wang, Hui Zhu, Zhijun Guo

Radiation Oncology · 2024

DOI: 10.1186/s13014-024-02458-x ↗

Kurz gefasst

Fachartikel in der Zeitschrift Radiation Oncology, 2024. Verfasst von Feihu Chen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, Ji…. Hauptthemen laut MEDLINE: Bevacizumab, Radiation Pneumonitis, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, CSCO Pilot Cancer Research Fund, Key Research and Development Program of Shandong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

First-line chemotherapy combined with bevacizumab is one of the standard treatment modes for patients with advanced non-small cell lung cancer (NSCLC). Thoracic radiotherapy (TRT) can provide significant local control and survival benefits to patients during the treatment of advanced NSCLC. However, the safety of adding TRT has always been controversial, especially because of the occurrence of radiation pneumonia (RP) during bevacizumab treatment. Therefore, in this study, we used an expanded sample size to evaluate the incidence of RP when using bevacizumab in combination with TRT. Patients and methods Using an institutional query system, all medical records of patients with NSCLC who received TRT during first-line chemotherapy combined with bevacizumab from 2017 to 2020 at Shandong Cancer Hospital and Institute were reviewed. RP was diagnosed via computed tomography and was classified according to the RTOG toxicity scoring system. The risk factors for RP were identified using univariate and multivariate analyses. The Kaplan–Meier method was used to calculate progression-free survival (PFS) and overall survival (OS).

Results

Ultimately, 119 patients were included. Thirty-eight (31.9%) patients developed Grade ≥ 2 RP, of whom 27 (68.1%) had Grade 2 RP and 11 (9.2%) had Grade 3 RP. No patients developed Grade 4 or 5 RP. The median time for RP occurrence was 2.7 months (range 1.2–5.4 months). In univariate analysis, male, age, KPS score, V 20 > 16.9%, V 5 > 33.6%, PTV (planning target volume)-dose > 57.2 Gy, and PTV-volume > 183.85 cm 3 were correlated with the occurrence of RP. In multivariate analysis, male, V 20 > 16.9%, and PTV-volume > 183.85 cm 3 were identified as independent predictors of RP occurrence. The mPFS of all patients was 14.27 (95% CI, 13.1–16.1) months. The one-year and two-year PFS rates were 64.9% and 20.1%, respectively. The mOS of all patients was 37.09 (95% CI, 33.8–42.0) months. The one-year survival rate of all patients was 95%, and the two-year survival rate was 71.4%.

Conclusions

The incidence of Grade ≥ 2 RP in NSCLC patients who received both bevacizumab and TRT was 31.9%. Restricting factors such as V 20 and PTV will help reduce the risk of RP in these patients. For patients who receive both bevacizumab and TRT, caution should be exercised when increasing TRT, and treatment strategies should be optimized to reduce the incidence of RP.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BevacizumabRadiation PneumonitisLung NeoplasmsCarcinoma, Non-Small-Cell LungHumansMaleFemaleMiddle AgedIncidenceRisk FactorsAgedRetrospective StudiesAdultChemoradiotherapyAntineoplastic Agents, ImmunologicalAged, 80 and overSurvival Rate

Stichwörter der Autor:innen

BevacizumabNon-small cell lung cancerRadiation pneumonitisThoracic radiotherapy

Substanzen

BevacizumabAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, China.
  • Department of Intensive Care Unit, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, 440 Jiyan Road, Jinan, 250117, Shandong, China. m17865587208@163.com.

Förderung

  • National Natural Science Foundation of China
  • CSCO Pilot Cancer Research Fund
  • Key Research and Development Program of Shandong Province

Zitieren

APA

Chen, F., Niu, J., Wang, M., Zhu, H., & Guo, Z. (2024). The incidence of and risk factors for radiation pneumonitis in patients treated with simultaneous bevacizumab and thoracic radiotherapy. Radiation Oncology. https://doi.org/10.1186/s13014-024-02458-x

Vancouver

Chen F, Niu J, Wang M, Zhu H, Guo Z. The incidence of and risk factors for radiation pneumonitis in patients treated with simultaneous bevacizumab and thoracic radiotherapy. Radiation Oncology. 2024. doi:10.1186/s13014-024-02458-x

BibTeX
@article{Chen2024,
  author = {Chen, Feihu and Niu, Jiling and Wang, Min and Zhu, Hui and Guo, Zhijun},
  title = {The incidence of and risk factors for radiation pneumonitis in patients treated with simultaneous bevacizumab and thoracic radiotherapy},
  journal = {Radiation Oncology},
  year = {2024},
  doi = {10.1186/s13014-024-02458-x}
}
Kostenlos starten →